| Sep-2024 | Jun-2024 | Mar-2024 | Dec-2023 | Sep-2023 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 52.76% | 0% | 52.79% | 52.79% | 52.79% |
Indian | 0% | 52.78% | 0% | 0% | 0% |
Total Promoter | - | - | - | - | - |
Institutions | 16.44% | 13.75% | 13.75% | 13.34% | 9.25% |
Non-Institutions | 30.63% | 33.29% | 33.28% | 33.69% | 37.56% |
Total Non-Promoter | 47.07% | 47.05% | 47.04% | 47.04% | 46.82% |
Custodian | 0.16% | 0.16% | 0.16% | 0.16% | 0.38% |
Total | 100% | 100% | 100% | 100% | 100% |
Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
